Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:anticoagulant |
| gptkbp:activeIngredient |
gptkb:clopidogrel
|
| gptkbp:approvalYear |
1997
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
B01AC04
|
| gptkbp:brand |
gptkb:Plavix
Iscover |
| gptkbp:CASNumber |
120202-66-6
|
| gptkbp:chemicalFormula |
C16H16ClNO2S·H2SO4
|
| gptkbp:contraindication |
active bleeding
hypersensitivity to clopidogrel |
| gptkbp:discoveredBy |
gptkb:Sanofi
|
| gptkbp:drugClass |
thienopyridine
|
| gptkbp:eliminationHalfLife |
6 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
clopidogrel bisulfate
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
P2Y12 receptor antagonist
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
bleeding
gastrointestinal upset bruising |
| gptkbp:usedFor |
prevention of blood clots
prevention of stroke prevention of myocardial infarction |
| gptkbp:bfsParent |
gptkb:Plavix
|
| gptkbp:bfsLayer |
6
|